|
1
|
Cunningham D, Allum WH, Stenning SP, et
al: MAGIC Trial Participants: Perioperative chemotherapy versus
surgery alone for resectable gastroesophageal cancer. N Engl J Med.
355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ychou M, Boige V, Pignon JP, et al:
Perioperative chemotherapy compared with surgery alone for
resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD
multicenter phase III trial. J Clin Oncol. 29:1715–1721. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ji J: Study on Neoadjuvant Chemotherapy
for Advanced Gastric Cancer[DB/OL]. http://www.clinicaltrials.gov/ct2/show/NCT02163291?cond=gastric+cancer&intr=chemotherapy&rank=33January
16–2015
|
|
4
|
Yamaguchi K, Nakagawa S, Yabusaki H and
Nashimoto A: Evaluation of neoadjuvant chemotherapy with
paclitaxel, 5-fluorouracil and cisplatin for advanced gastric
cancer with pyloric stenosis. Gan To Kagaku Ryoho. 34:2241–2244.
2007.(In Japanese). PubMed/NCBI
|
|
5
|
Sun Y, Xu X, Hu J, et al: Efficacies of
neoadjuvant chemotherapy plus nutritional support in advanced
gastric cancer complicated with pylori obstruction. Zhonghua Yi Xue
Za Zhi. 94:584–586. 2014.(In Chinese). PubMed/NCBI
|
|
6
|
Yasuyama A, Mikata S, Soma Y, et al: Two
cases of human epidermal growth factor receptor 2-positive advanced
gastric cancer successfully treated with S-1, cisplatin, and
trastuzumab combination therapy followed by curative resection. Gan
To Kagaku Ryoho. 40:2203–2206. 2013.(In Japanese). PubMed/NCBI
|
|
7
|
Nakayama Y, Kawasaki H, Wajima N, et al:
Two cases of stage IV gastric cancer treated by resection of the
primary tumor after chemotherapy combined with trastuzumab. Gan To
Kagaku Ryoho. 40:2188–2190. 2013.(In Japanese). PubMed/NCBI
|
|
8
|
Du Y, Cheng X, Xu Z, et al: D2 plus
radical resection combined with perioperative chemotherapy for
advanced gastric cancer with pyloric obstruction. Chin J Cancer
Res. 25:479–481. 2013.PubMed/NCBI
|
|
9
|
Yamaguchi K, Nakagawa S, Yabusaki H and
Nashimoto A: A case of advanced gastric cancer responding
remarkably to paclitaxel + low-dose FP therapy in a neoadjuvant
setting. Gan To Kagaku Ryoho. 33:1163–1166. 2006.(In Japanese).
PubMed/NCBI
|
|
10
|
Shikano T, Koshikawa K, Kiriyama K, et al:
Two cases of advanced gastric cancer with peritoneal dissemination
acquired long-term response three years or more by postoperative
treatment with oral anticancer drug TS-1. Gan To Kagaku Ryoho.
33:87–90. 2006.(In Japanese). PubMed/NCBI
|
|
11
|
Sakurai K, Nashimoto A and Yabusaki H: A
case of advanced gastric cancer showing pylorus stenosis with
multiple liver metastases, that respond remarkably to neoadjuvant
chemotherapy of combined TXL and low-dose FP. Gan To Kagaku Ryoho.
30:407–411. 2003.(In Japanese). PubMed/NCBI
|
|
12
|
Hokita S, Takatori H, Ishigami S, et al: A
case of advanced type 4 gastric cancer with peritonitis
dissemination, navel metastasis effectively treated with combined
chemotherapy of biweekly paclitaxel (TXL) and TS-1. Gan To Kagaku
Ryoho. 30:1343–1346. 2003.(In Japanese). PubMed/NCBI
|
|
13
|
Tanabe T, Nashimoto A, Sasaki J, et al: A
case of advanced gastric cancer with abdominal para-aortic lymph
node metastasis successfully treated with FLP therapy. Gan To
Kagaku Ryoho. 26:2073–2076. 1999.(In Japanese). PubMed/NCBI
|
|
14
|
Iwamoto S, Kimoto M, Mure T, et al: A case
of papillary adenocarcinoma of the stomach with liver metastases
and carcinomatous peritonitis treated effectively by
methotrexate/5-fluorouracil sequential chemotherapy. Gan To Kagaku
Ryoho. 24:2005–2009. 1997.(In Japanese). PubMed/NCBI
|
|
15
|
Castellanos AE, Stein EA, Mann BD and
Podolsky ER: Gastric Outlet Obstruction[DB/OL]. http://emedicine.medscape.com/article/190621-overview2013January
16–2015
|
|
16
|
National Center for biotechnology
Information, . Gastric Outlet Obstruction[DB/OL]. http://www.ncbi.nlm.nih.gov/mesh/68017219January
16–2015
|
|
17
|
Chen JH, Wu CW, Lo SS, et al: Outcome of
distal gastric cancer with pyloric stenosis after curative
resection. Eur J Surg Oncol. 33:556–560. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Watanabe A, Maehara Y, Okuyama T, et al:
Gastric carcinoma with pyloric stenosis. Surgery. 123:330–334.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mackay S, Hayes T and Yeo A: Management of
gastric cancer. Aust Fam Physician. 35:208–211. 2006.PubMed/NCBI
|
|
20
|
Stupart DA, Panieri E and Dent DM:
Gastrojejunostomy for gastric outlet obstruction in patients with
gastric carcinoma. S Afr J Surg. 44:52–54. 2006.PubMed/NCBI
|
|
21
|
Johnson CD and Ellis H: Gastric outlet
obstruction now predicts malignancy. Br J Surg. 77:1023–1024. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi YB: Laparoscopic gatrojejunostomy for
palliation of gastric outlet obstruction in unresectable gastric
cancer. Surg Endosc. 16:1620–1626. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Navarra G, Musolino C, Venneri A, et al:
Palliative antecolic isoperistaltic gastrojejunostomy: A randomized
controlled trial comparing open and laparoscopic approaches. Surg
Endosc. 20:1831–1834. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nashimoto A, Yabusaki H and Nakagawa S:
Treatment strategy for the type IV gastric cancer—from the
standpoint of the surgery. Gan To Kagaku Ryoho. 34:983–987.
2007.(In Japanese). PubMed/NCBI
|
|
25
|
Takeno A, Takiguchi S, Fujita J, et al:
Clinical Study Group of Osaka University (CSGO), Upper GI Group:
Clinical outcome and indications for palliative gastrojejunostomy
in unresectable advanced gastric cancer: Multi-institutional
retrospective analysis. Ann Surg Oncol. 20:3527–3533. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shrikhande SV, Sirohi B, Barreto SG, et
al: Indian Council of Medical Research consensus document for the
management of gastric cancer. Indian J Med Paediatr Oncol.
35:239–243. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
National Comprehensive Cancer Network, .
The NCCN Clinical Practice Guidelines in Oncology for Gastric
Cancer (Version 1.2014) [EB/OL]. 2014 5 30 2015 1 16http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
|
|
28
|
Jeurnink SM, van Eijck CH, Steyerberg EW,
et al: Stent versus gastrojejunostomy for the palliation of gastric
outlet obstruction: A systematic review. BMC Gastroenterol.
7:182007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fiori E, Lamazza A, Demasi E, et al:
Endoscopic stenting for gastric outlet obstruction in patients with
unresectable antro pyloric cancer. Systematic review of the
literature and final results of a prospective study. The point of
view of a surgical group. Am J Surg. 206:210–217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mercadante S: Parenteral versus enteral
nutrition in cancer patients: indications and practice. Support
Care Cancer. 6:85–93. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lindh A, Cedermark B, Blomgren H, et al:
Enteral and parenteral nutrition in anorectic patients with
advanced gastrointestinal cancer. J Surg Oncol. 33:61–65. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Adler DG and Baron TH: Endoscopic
palliation of malignant gastric outlet obstruction using
self-expanding metal stents: Experience in 36 patients. Am J
Gastroenterol. 97:72–78. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Becker K, Mueller JD, Schulmacher C, et
al: Histomorphology and grading of regression in gastric carcinoma
treated with neoadjuvant chemotherapy. Cancer. 98:1521–1530. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Oken MM, Creech RH, Tormey DC, et al:
Toxicity and response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsuburaya A, Mizusawa J, Tanaka Y, et al:
Stomach Cancer Study Group of the Japan Clinical Oncology Group:
Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2
gastrectomy with para-aortic lymph node dissection for gastric
cancer with extensive lymph node metastasis. Br J Surg.
101:653–660. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hirakawa M, Sato Y, Ohnuma H, et al: A
phase II study of neoadjuvant combination chemotherapy with
docetaxel, cisplatin, and S-1 for locally advanced resectable
gastric cancer: Nucleotide excision repair (NER) as potential
chemoresistance marker. Cancer Chemother Pharmacol. 71:789–797.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen SS, Yang XC, Chi F, et al: A phase II
study of preoperative chemotherapy with modified FOLFOX6 followed
by surgery and postoperative chemoradiation in patients with
localized gastric adenocarcinoma. Oncol Res. 20:327–332. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun XC, Lin J and Ju AH: Treatment of
Borrmann type IV gastric cancer with a neoadjuvant chemotherapy
combination of docetaxel, cisplatin and 5-fluorouracil/leucovorin.
J Int Med Res. 39:2096–2102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Spizzo G, Öfner D, de Vries A, et al:
Preoperative chemotherapy with cisplatin and docetaxel followed by
surgery and clip-oriented postoperative chemoradiation in patients
with localized gastric or gastroesophageal junction adenocarcinoma:
Results from a phase II feasibility study. Ann Surg Oncol.
18:677–683. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li T and Chen L: Efficacy and safety of
SOX regimen as neoadjuvant chemotherapy for advanced gastric
cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 14:104–106. 2011.(In
Chinese). PubMed/NCBI
|
|
42
|
Yoshikawa T, Omura K, Kobayashi O, et al:
A phase II study of preoperative chemotherapy with S-1 plus
cisplatin followed by D2/D3 gastrectomy for clinically
serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg
Oncol. 36:546–551. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Qu JJ, Shi YR, Liu FR, et al: A clinical
study of paclitaxel combined with FOLFOX4 regimen as neoadjuvant
chemotherapy for advanced gastric cancer. Zhonghua Wei Chang Wai Ke
Za Zhi. 13:664–667. 2010.(In Chinese). PubMed/NCBI
|
|
44
|
Tsuburaya A, Nagata N, Cho H, Hirabayashi
N, Kobayashi M, Kojima H, Munakata Y, Fukushima R, Kameda Y,
Shimoda T, et al: Phase II trial of paclitaxel and cisplatin as
neoadjuvant chemotherapy for locally advanced gastric cancer.
Cancer Chemother Pharmacol. 71:1309–1314. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Biffi R, Fazio N, Luca F, et al: Surgical
outcome after docetaxel-based neoadjuvant chemotherapy in
locally-advanced gastric cancer. World J Gastroenterol. 16:868–874.
2010.PubMed/NCBI
|
